BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

...IAP antagonist birinapant reduced liver parasite burden, delayed and attenuated blood-stage parasitemia and improved survival. Birinapant...
...I and II testing for hematologic and solid cancer indications. Medivir AB (SSE:MVIR B) has birinapant...
BioCentury | Nov 3, 2016
Company News

TetraLogic, Medivir deal

...Medivir will acquire birinapant and suberohydroxamic acid phenyl ester (SHAPE) from TetraLogic for $12 million up...
...capped at 13%. TetraLogic is also eligible for up to $130 million in milestones for birinapant...
...cell lymphoma. Medivir plans to begin a Phase III trial for the indication in 2H17. Birinapant...
BioCentury | Apr 4, 2016
Finance

None shall pass

...million last quarter. In January, the company terminated for futility a Phase II trial of birinapant...
BioCentury | Feb 1, 2016
Clinical News

Birinapant: Phase II discontinued

...62 evaluable azacitidine-naive patients with higher risk MDS showed that twice-weekly 13 mg/m 2 IV birinapant...
...trial (see BioCentury, July 27, 2015). TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711...
BioCentury | Jul 27, 2015
Clinical News

Birinapant: Preliminary Phase IIa data

...in a double-blind, placebo-controlled, international Phase IIa trial showed that twice-weekly 13 mg/m 2 IV birinapant...
...case of stable disease. Three patients discontinued the trial before receiving 4 cycles of treatment. Birinapant...
...as the most common adverse events. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711...
BioCentury | May 25, 2015
Clinical News

Birinapant: Phase Ib/IIa halted

...TetraLogic temporarily halted enrollment in a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV birinapant following...
...its ongoing cancer trials are not affected. The trial is evaluating multiple ascending doses of birinapant...
...the trials are expected this year. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711...
BioCentury | May 18, 2015
Company News

TetraLogic, Merck deal

...TetraLogic and Merck will jointly conduct a Phase I trial evaluating TetraLogic’s birinapant in combination with...
...study, and Merck will provide Keytruda. The study is slated to begin late this year. Birinapant...
BioCentury | Jun 30, 2014
Clinical News

Birinapant: Preliminary Phase Ib/IIa data

...the dose-escalation Phase Ib portion of the open-label, U.S. Phase Ib/IIa TL32711-0087 trial showed that birinapant...
...Phase IIa/IIb trial evaluating birinapant plus azacitidine as first-line treatment in 158 higher-risk MDS patients. Birinapant...
...N.J.) markets Vidaza azacitidine for MDS. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711...
BioCentury | Feb 3, 2014
Company News

TetraLogic, Walter and Eliza Hall Institute of Medical Research deal

...The institute and TetraLogic partnered to develop birinapant to treat viral infections. The institute granted TetraLogic...
...plans to begin a Phase I trial with birinapant to treat HBV infection in 1Q15. Birinapant...
...small molecule peptidomimetic of diablo homolog (DIABLO; SMAC ) that selectively antagonizes multiple IAP proteins. Birinapant...
BioCentury | Dec 13, 2013
Financial News

TetraLogic raises $50.1 million in IPO

...sell 6.4 million shares at $13-$15. Oppenheimer; Guggenheim; and Needham are underwriters. TetraLogic's birinapant (formerly TL32711...
Items per page:
1 - 10 of 20